| Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases (NCT07258147) | Sichuan University | 2026-10-31 |
| Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma (NCT07767630) | Sichuan University | 2026-07-21 |
| Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study (NCT07665697) | Sichuan University | 2026-06-30 |
| A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC (NCT07692048) | Sichuan University | 2026-06-30 |
| Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study (NCT07665736) | Sichuan University | 2026-06-30 |
| Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer (NCT07637786) | Sichuan University | 2026-06-20 |
| Intensive Nutritional Support in Conversion Therapy for Locally Advanced Unresectable ESCC (NCT07519486) | Sichuan University | 2026-04-01 |
| Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (NCT07501169) | Sichuan University | 2026-04-01 |
| Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma (NCT07488624) | Sichuan University | 2026-03-01 |
| Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection (NCT07362732) | Sichuan University | 2026-02-01 |
| Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma (NCT07374250) | Sichuan University | 2026-02-01 |
| Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection (NCT07332663) | Sichuan University | 2026-01-01 |
| Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial (NCT07211009) | Sichuan University | 2025-10-15 |
| An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer (NCT06883552) | Sichuan University | 2025-10-01 |
| Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer (NCT07154108) | Sichuan University | 2025-09-01 |
| Lateral Positioning for Extubation After Adenotonsillectomy (NCT07108218) | Sichuan University | 2025-08-20 |
| Oncolytic Virus in Esophageal Squamous Cell Carcinoma (NCT07061704) | Sichuan University | 2025-08-01 |
| Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma (NCT07067450) | Sichuan University | 2025-07-20 |
| The Intensive Nutritional Support in Esophageal Cancer Undergoing Neoadjuvant Therapy (NCT07067359) | Sichuan University | 2025-07-15 |
| Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer (NCT06877299) | Sichuan University | 2025-07-04 |
| A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC (NCT06951464) | Sichuan University | 2025-06-25 |
| Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies (NCT07004244) | Sichuan University | 2025-06-05 |
| NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC (NCT06966583) | Sichuan University | 2025-05-01 |
| Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC (NCT06348797) | Sichuan University | 2025-04-03 |
| A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC (NCT06769295) | Sichuan University | 2025-02-01 |
| Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC (NCT06769971) | Sichuan University | 2025-02-01 |
| Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC (NCT06732258) | Sichuan University | 2025-01-10 |
| Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC (NCT07748325) | Sichuan University | 2025-01-10 |
| Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma (NCT06675201) | Sichuan University | 2024-10-01 |
| Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma (NCT06446726) | Sichuan University | 2024-06-30 |
| Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer (NCT06359821) | Sichuan University | 2024-05-17 |
| Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC (NCT06477523) | Sichuan University | 2024-05-16 |
| Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer (NCT06403878) | Sichuan University | 2024-05-01 |
| Effects of Aromatherapy on Anxiety and Pain During Dental Treatment in Adults (NCT06347679) | Sichuan University | 2024-05-01 |
| Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC (NCT06346808) | Sichuan University | 2024-05-01 |
| Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer (NCT06431685) | Sichuan University | 2024-04-25 |
| Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors (NCT06349837) | Sichuan University | 2024-04-18 |
| Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC (NCT06217757) | Sichuan University | 2024-04-18 |
| Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer (NCT06344156) | Sichuan University | 2024-04-01 |
| Phase II Trial: Low-Dose Radiation + SBRT + Sintilimab + Chemotherapy vs. Sintilimab + Chemotherapy in Locally Advanced or Metastatic Squamous Cell Lung Cancer (NCT06121505) | Sichuan University | 2024-03-01 |
| Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II (NCT06195189) | Sichuan University | 2024-02-29 |
| HIPEC Combined With SOX and Sintilimab in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis (NCT06213519) | Sichuan University | 2024-02-20 |
| Billroth II With Braun Anastomosis After Radical Distal Gastrectomy for Gastric Cancer (NCT06229197) | Sichuan University | 2024-02-01 |
| Effect of TEE-guided Non-fluid Limited Combined With Dobutamine on Hepatic Venous Blood Flow Spectrum (NCT06210217) | Sichuan University | 2024-02-01 |
| Compared Unidirectional Valve Apparatus and Occluding the Non-ventilated Endobronchial Lumen for Lung Collapse. (NCT06210256) | Sichuan University | 2024-01-25 |
| Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors (NCT06084286) | Sichuan University | 2024-01-01 |
| MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib (NCT06075225) | Sichuan University | 2023-10-01 |
| Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT (NCT06075238) | Sichuan University | 2023-10-01 |
| Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC (NCT06033118) | Sichuan University | 2023-10-01 |
| Immune Reconstitution After Allo-HSCT and Blinatumomab (NCT06075212) | Sichuan University | 2023-10-01 |
| Dead Mesenchymal Stem Cells for Radiation Lung Injury (NCT06021067) | Sichuan University | 2023-09-10 |
| Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL (NCT06111625) | Sichuan University | 2023-09-10 |
| Low-Dose Involved-Field Radiotherapy Plus Immunochemotherapy for ESCC (NCT06603402) | Sichuan University | 2023-08-24 |
| Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer (NCT05900921) | Sichuan University | 2023-07-01 |
| To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (NCT05948449) | Sichuan University | 2023-07-01 |
| Fractionated Busulfan Conditioning Regimen for Allo-HSCT in Non-remission Myeloid Malignancies (NCT05807659) | Sichuan University | 2023-03-16 |
| Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC (NCT05765825) | Sichuan University | 2023-03-07 |
| Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases (NCT05477927) | Sichuan University | 2023-02-15 |
| Chidamide Prevents Recurrence of High-risk AML After Allo-HSCT (NCT05682755) | Sichuan University | 2022-12-22 |
| CXCR4 Modified Anti-BCMA CAR T Cells for Multiple Myeloma (NCT04727008) | Sichuan University | 2022-09-21 |
| ChiCGB vs BEAM in High-risk or R/R Lymphomas (NCT05466318) | Sichuan University | 2022-07-01 |
| A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC (NCT05317325) | Sichuan University | 2022-04-01 |
| Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell Transplantation (NCT05250362) | Sichuan University | 2022-03-01 |
| Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors (NCT05235607) | Sichuan University | 2022-03-01 |
| High-Dose Gemcitabine, Busulfan, and Thiotepa Followed by ASCT in Primary Central Nervous System Lymphoma (NCT07014943) | Sichuan University | 2022-01-01 |
| A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer (NCT05186506) | Sichuan University | 2022-01-01 |
| Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC. (NCT05615142) | Sichuan University | 2021-12-15 |
| Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer (NCT05023928) | Sichuan University | 2021-09-01 |
| Effect of Lactulose and/or Polyethylene Glycol Solution for Bowel Preparation for Colonscopy Procedures (NCT05076799) | Sichuan University | 2021-09-01 |
| Comparative Effect of Clear Aligner Mandibular Advancement and Twin Block Appliances in Class II Malocclusion (NCT06609733) | Sichuan University | 2021-08-01 |
| Effects of Spousal Participation in Breastfeeding Interventions at Different Perinatal Stages on Mothers' Coparenting Cognition and Infant Feeding Patterns (NCT07461038) | Sichuan University | 2020-08-20 |
| ATG-008 Combined With Toripalimab in Advanced Solid Tumors (NCT04337463) | Sichuan University | 2020-04-23 |
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (NCT04263870) | Sichuan University | 2020-03-01 |
| Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus (NCT04069949) | Sichuan University | 2019-12-01 |
| Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis (NCT07549269) | Sichuan University | 2019-12-01 |
| Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma (NCT04156958) | Sichuan University | 2019-12-01 |
| Personalized DC Vaccine for Postoperative Cancer (NCT04147078) | Sichuan University | 2019-06-01 |
| Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients (NCT03812549) | Sichuan University | 2019-01-18 |
| Tofacitinib Combined With Chidamide in R/R ENKTCL (NCT03598959) | Sichuan University | 2019-01-01 |
| Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma (NCT03602131) | Sichuan University | 2019-01-01 |
| Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT (NCT03336632) | Sichuan University | 2019-01-01 |
| Ruxolitinib Plus LVP in Patients With R/R ETP-ALL (NCT03613428) | Sichuan University | 2018-12-01 |
| A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients (NCT03373955) | Sichuan University | 2017-11-23 |